天士力首年融合业绩靓丽，2025年净利预增15.68%

Core Viewpoint - The integration of Tian Shi Li into the China Resources Sanjiu system is expected to enhance operational efficiency and drive growth, with the company forecasting a net profit of 1.105 billion yuan for 2025, representing a year-on-year increase of 15.68% [1][2]. Group 1: Financial Performance - The company anticipates total revenue of 8.236 billion yuan for 2025, with a net profit attributable to shareholders of 1.105 billion yuan, reflecting a 15.68% increase year-on-year [2]. - Basic earnings per share are projected to be 0.74 yuan, marking a 15.63% growth [4]. Group 2: Strategic Integration - Tian Shi Li is positioned as a key component of the "one body, two wings" strategy of China Resources Sanjiu, focusing on "innovation-driven" growth [2]. - The company is undergoing a comprehensive integration process with China Resources Sanjiu, enhancing management systems through value, business, organizational, and cultural restructuring [2]. - The integration aims to optimize operational management and improve asset quality, leveraging resources from China Resources Sanjiu in management, channels, and industry [2][3]. Group 3: Research and Development - Tian Shi Li has a robust pipeline with 31 innovative drugs under development, including nearly 20 traditional Chinese medicine products in late-stage clinical trials and several biopharmaceuticals targeting high-demand areas [4]. - The market perceives the company as a traditional player focused on Chinese medicine, but there is potential for value reassessment due to its extensive R&D pipeline [4].